ACAAI Late Breaker: Dupilumab Curbs Itching and Hives in Phase 3 CSU Trial
Dupilumab (Dupixent, Sanofi & Regeneron) performed well in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who received background therapy with antihistamines, according to a late-breaking oral presentation at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, MA. Treatment with dupilumab significantly reduced itch and urticaria activity scores […]